US Bancorp’s DiaMedica Therapeutics DMAC Stock Holding History

US Bancorp’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.5K	Sell	4,335 -187	-4%	-$1.15K	﹤0.01%	3027
2026 Q1	$30.6K	Hold	4,522	–	–	﹤0.01%	2918
2025 Q4	$36K	Buy	4,522 +187	+4%	+$1.4K	﹤0.01%	2834
2025 Q3	$29.8K	Hold	4,335	–	–	﹤0.01%	2905
2025 Q2	$16.9K	Hold	4,335	–	–	﹤0.01%	3234
2025 Q1	$16.4K	Hold	4,335	–	–	﹤0.01%	3261
2024 Q4	$23.5K	Hold	4,335	–	–	﹤0.01%	3094
2024 Q3	$18.2K	Hold	4,335	–	–	﹤0.01%	3160
2024 Q2	$12.8K	Hold	4,335	–	–	﹤0.01%	3226
2024 Q1	$12K	Hold	4,335	–	–	﹤0.01%	3273
2023 Q4	$12.3K	Hold	4,335	–	–	﹤0.01%	3244
2023 Q3	$11.2K	Hold	4,335	–	–	﹤0.01%	3130
2023 Q2	$18.7K	Hold	4,335	–	–	﹤0.01%	3008
2023 Q1	$6.63K	Hold	4,335	–	–	﹤0.01%	3427
2022 Q4	$6.85K	Hold	4,335	–	–	﹤0.01%	3412
2022 Q3	$5K	Hold	4,335	–	–	﹤0.01%	3583
2022 Q2	$9K	Hold	4,335	–	–	﹤0.01%	3387
2022 Q1	$11K	Hold	4,335	–	–	﹤0.01%	3336
2021 Q4	$16K	Hold	4,335	–	–	﹤0.01%	3228
2021 Q3	$17K	Hold	4,335	–	–	﹤0.01%	3201
2021 Q2	$19K	Hold	4,335	–	–	﹤0.01%	3159
2021 Q1	$40K	Hold	4,335	–	–	﹤0.01%	2687
2020 Q4	$44K	Hold	4,335	–	–	﹤0.01%	2561
2020 Q3	$18K	Buy	+4,335	New	+$22.9K	﹤0.01%	2851

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

US Bancorp's DMAC Position: Q2 2026 in Review

US Bancorp reduced its DiaMedica Therapeutics (DMAC) stake by 4.1% in Q2 2026, selling an estimated $1.15K and leaving 4,335 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3027.

US Bancorp first reported a position in DMAC in Q3 2020 and has held it in 24 quarters since. The position peaked at $44K in Q4 2020. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

US Bancorp held 4,335 shares of DiaMedica Therapeutics worth $30.5K as of Q2 2026.
US Bancorp sold 187 DiaMedica Therapeutics shares in Q2 2026, an estimated $1.15K.
DiaMedica Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3027 holding.
US Bancorp first reported a position in DiaMedica Therapeutics in Q3 2020 and has held it in 24 quarters since.
US Bancorp's DiaMedica Therapeutics position peaked at $44K in Q4 2020.
89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.